Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Jin, Long ^a,b   Lim, Sun Woo ^a,b   Doh, Kyoung Chan ^a,b   Piao, Shang Guo ^a,b   Jin, Jian ^a,b   Heo, Seong Beom ^a,b   Chung, Byung Ha ^a,b   Yang, Chul Woo ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; MK 0626; TACROLIMUS; UNCLASSIFIED DRUG; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; PROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; MALE; METABOLIC PARAMETERS; NONHUMAN; OXIDATIVE RESISTANCE; OXIDATIVE STRESS; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DISEASE; PANCREAS ISLET INJURY; PROTECTION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DNA DAMAGE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; PANCREAS ISLET; PATHOLOGY; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; DEOXYGUANOSINE; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DNA DAMAGE; ISLETS OF LANGERHANS; MALE; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 84903522672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100798     Document Type: Article

References (39)

1. Sharif A, de Vries APJ, Porrini E, Hecking M, Saemann M (2012) Clinical trials for treatment of NODAT: time to collaborate. Transplantation 94: e23-24.
2. Valderhaug TG, HjelmesÃth J, Hartmann A, RÃislien J, Bergrem HA, et al. (2011) The association of early post-transplant glucose levels with long-term mortality. Diabetologia 54: 1341-1349.
3. Hwang H, Ghee J, Song J, Piao S, Yang C (2012) Comparison of adverse drug reaction profiles of two tacrolimus formulations in rats. Immunopharmacology and immunotoxicology 34: 434-442.
4. Ishizuka J, Gugliuzza KK, Wassmuth Z, Hsieh J, Sato K, et al. (1993) Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 56: 1486-1490. (Pubitemid 24018809)
5. Edmondson SD, Mastracchio A, Mathvink RJ, He J, Harper B, et al. (2006) (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4] triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 49: 3614-3627. (Pubitemid 43902466)
6. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, et al. (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48: 141-151. (Pubitemid 40105255)
7. Shih CM, Chen YH, Yi WL, Tsao NW, Wu SC, et al. (2013) MK-0626, A Dipeptidyl Peptidase-4 Inhibitor, Improves Neovascularization by Increasing Both the Number of Circulating Endothelial Progenitor Cells and Endothelial Nitric Oxide Synthetase Expression. Curr Med Chem.
8. Glorie LLF, Verhulst A, Matheeussen V, Baerts L, Magielse J, et al. (2012) DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. American journal of physiology Renal physiology 303: F681-F688.
9. Joo KW, Kim S, Ahn SY, Chin HJ, Chae DW, et al. (2013) Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol 14: 98.
10. Katagiri D, Hamasaki Y, Doi K, Okamoto K, Negishi K, et al. (2013) Protection of glucagon-like Peptide-1 in Cisplatin-induced renal injury elucidates gutkidney connection. Journal of the American Society of Nephrology 24: 2034-2043.
11. Mu J, Petrov A, Eiermann G, Woods J, Zhou YP, et al. (2009) Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. European journal of pharmacology 623: 148-154.
12. Park C, Kim H, Ko S, Lim J, Ryu G, et al. (2007) Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. Journal of the American Society of Nephrology 18: 1227-1238. (Pubitemid 46536909)
13. Lim S, Doh K, Jin L, Piao S, Heo S, et al. (2013) Oral administration of ginseng ameliorates cyclosporine-induced pancreatic injury in an experimental mouse model. PLoS ONE 8: e72685-e72685.
14. Piao S, Bae S, Lim S, Song J-H, Chung B, et al. (2012) Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction. Transplantation 93: 383-389.
15. Lim S, Hyoung B, Piao S, Doh K, Chung B, et al. (2012) Chronic cyclosporine nephropathy is characterized by excessive autophagosome formation and decreased autophagic clearance. Transplantation 94: 218-225.
16. 2-cells from cytokine-induced apoptosis by alleviating apoptotic pathways and activating anti-apoptotic pathways of Nrf2-HO-1 and Sirt1. Toxicology and applied pharmacology 252: 47-54.
17. 2-cells dysfunction through autophagy dysfunction. Endocrinology 154: 2626-2639.
18. Bank HL (1987) Assessment of islet cell viability using fluorescent dyes. Diabetologia 30: 812-816.
19. Bank HL (1988) Rapid assessment of islet viability with acridine orange and propidium iodide. In vitro cellular & developmental biology 24: 266-273.
20. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, et al. (2012) Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 340: 248-255.
21. Iwasaki K (2007) Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. drug metabolism and pharmacokinetics 22: 328-335.
22. Krishna R, Bergman A, Larson P, Cote J, Lasseter K, et al. (2007) Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. The Journal of clinical pharmacology 47: 165-174. (Pubitemid 46146482)
23. Yoon H, Lim S, Piao S, Song JH, Kim J, et al. (2012) Statin Upregulates the Expression of Klotho, an Anti-Aging Gene, in Experimental Cyclosporine Nephropathy. Nephron Experimental nephrology 120: e123-e133.
24. Lee E, Ryu GR, Ko SH, Ahn YB, Yoon KH, et al. (2011) Antioxidant treatment may protect pancreatic beta cells through the attenuation of islet fibrosis in an animal model of type 2 diabetes. Biochem Biophys Res Commun 414: 397-402.
25. Lee YE, Kim JW, Lee EM, Ahn YB, Song KH, et al. (2012) Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS One 7: e50412.
26. Chang G, Zhang P, Ye L, Lu K, Wang Y, et al. (2013) Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model. European journal of pharmacology 718: 105-113.
27. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, et al. (2009) Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefe's archive for clinical and experimental ophthalmology 247: 699-706.
28. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, et al. (2009) Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 380: 44-49.
29. Kan M, Guo G, Singh B, Singh V, Zochodne D (2012) Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. Journal of neuropathology and experimental neurology 71: 494-510.
30. Zhang Y, Zhang J, Wang Q, Lei X, Chu Q, et al. (2011) Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Investigative ophthalmology & visual science 52: 278-285.
31. Haidinger M, Werzowa J, Hecking M, Antlanger M, Stemer G, et al. (2013) Efficacy and Safety of Vildagliptin in New-Onset Diabetes After Kidney Transplantation-A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Transplant.
32. Lane J, Odegaard D, Haire C, Collier D, Wrenshall L, et al. (2011) Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 92: e56-e57.
33. Strom Halden TA, Asberg A, Vik K, Hartmann A, Jenssen T (2014) Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant.
34. Song HK, Han DH, Song JH, Ghee JY, Piao SG, et al. (2009) Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats. American journal of transplantation 9: 2024-2033.
35. Ghiani BU, Masini MA (1995) Angiotensin II binding sites in the rat pancreas and their modulation after sodium loading and depletion. Comparative biochemistry and physiology Part A, Physiology 111: 439-444.
36. Shihab FS, Bennett WM, Tanner AM, Andoh TF (1997) Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 64: 1829-1837. (Pubitemid 28041725)
37. Stillman IE, Andoh TF, Burdmann EA, Bennett WM, Rosen S (1995) FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. Laboratory Investigation 73: 794-803. (Pubitemid 26002338)
38. Yuan L, Li X, Li J, Li HL, Cheng SS (2013) Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 50: 479-488.
39. Yuan L, Li X, Xu GL, Qi CJ (2010) Effects of renin-angiotensin system blockade on islet function in diabetic rats. Journal of endocrinological investigation 33: 13-19.